Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Acomplia (Rimonabant) – Investigational Agent for the Management of Obesity

Drug (Brand/Generic)

Acomplia / rimonabant

Company/Licensee

Sanofi-Aventis

Therapy Class

Cannabinoid receptor antagonist

Product Description

Selective inhibitor of the CB1 endocannabinoid receptor

Current Indication

Treatment of obesity in combination with dietary control

Market Sector

Nutrition

Development Status

Withdrawn Europe; NDA withdrawn in US
Expand

Go Top